Pharmacodynamics
Allopurinol is a structural analog of the natural purine base, hypoxanthine. After ingestion, allopurinol is metabolized in the liver to its active metabolite, oxypurinol (alloxanthin), which acts as an inhibitor of the enzyme xanthine oxidase. Xanthine oxidase mediates the physiological breakdown of the purine bases adenine and guanine to uric acid. In some cases, this process may be exacerbated, such as in individuals with tumor disease or those with a family history of gout. As a result, the uric acid level in the blood rises too high and deposits of uric acid crystals form in the joints of the affected persons. Allopurinol prevents the conversion of xanthine to uric acid, which is why increased xanthine is excreted by the kidneys and the uric acid level is lowered.
Pharmacokinetics
This drug is absorbed approximately 90% from the gastrointestinal tract. The maximum plasma level usually occurs after 1.5 hours. Plasma protein binding is extremely low and can therefore be neglected. Allopurinol is rapidly metabolized to the corresponding xanthine analogue, oxipurinol (alloxanthine), which is also an inhibitor of the enzyme xanthine oxidase. Allopurinol and oxypurinol are converted to their respective ribonucleotides via the "purine salvage pathway" and excreted. Approximately 80% of orally ingested allopurinol (and metabolites) are excreted in the urine. Approximately 20% of ingested allopurinol is excreted in the feces.
Drug Interactions
The drug-drug interactions associated with the use of allopurinol are extensive.
- Azathioprine and 6-mercaptopurine: Azathioprine is metabolized to 6-mercaptopurine, which in turn is inactivated by the action of xanthine oxidase - the target of allopurinol. Simultaneous administration of allopurinol with either of these drugs at the normal dose will result in an overdose of both drugs. Therefore, only one-fourth of the usual dose of 6-mercaptopurine or azathioprine should be given.
- Didanosine: Cmax and AUC values of plasma didanosine were approximately doubled with concomitant allopurinol treatment. Therefore, concomitant use is not recommended. If concomitant use is necessary, the dose must be reduced and the patient closely monitored.
Allopurinol may also increase the activity or half-life of the following drugs, in order of severity and safety of interaction:
- Ciclosporin
- coumarin anticoagulants, such as warfarin
- Vidarabine
- Chlorpropamide
- Phenytoin
- Theophylline
- Cyclophosphamide
- Doxorubicin
- Bleomycin
- Procarbazine
- Mechlorethamine
Concomitant administration of the following drugs may decrease the effectiveness of allopurinol or shorten its half-life:[9]
- Salicylates and drugs that increase the secretion of uric acid
- Furosemide
Concomitant administration of the following drugs may cause hypersensitivity reactions or rash:
- Ampicillin and amoxicillin
- diuretics, especially thiazides, especially in renal failure
- ACE inhibitors